Close Menu

JP Morgan Healthcare Conference

"Over time, there is no reason why we can't build an instrument that costs $50,000, $100,000, $300,000, so we have got a tremendous portfolio opportunity ahead of us over time," a PacBio official said.

Waters, Genomic Health, Bio-Rad, Agilent, and Sigma-Aldrich were among the presenters on the first day of the conference.

Gen-Probe just launched the Panther system in Europe with its initial menu focused on STD tests. The firm believes menu expansion will drive double-digit sales growth for years to come.

Officials from Qiagen, Cepheid, Gen-Probe, Celera, and Luminex provided updates on recently launched and upcoming assays and instrument systems.

Officials from the company said Thermo Fisher's R&D investments would target mass spectrometry, specialty diagnostics, and bioscience reagents.

Genomic Health will also hire additional sales people in connection with the launch, President and CEO Kim Popovits said yesterday at the JP Morgan Healthcare Conference.

A Beckman Coulter official provided an update on revenue guidance and the firm's pending molecular diagnostics system; while an Agilent executive discussed the company's pending Varian acquisition and new UHPLC system.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.